Halozyme Therapeutics HALO Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's interest expense?
- Halozyme Therapeutics (HALO) reported interest expense of $5.51M in Q1 2026.
- How has Halozyme Therapeutics's interest expense changed year-over-year?
- Halozyme Therapeutics's interest expense increased by 21.7% year-over-year, from $4.53M to $5.51M.
- What is the long-term trend for Halozyme Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's interest expense has grown at a 24.6% compound annual growth rate (CAGR), from $7.53M to $18.13M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.